Continuous monitoring of blood pressure is of vital importance to prevent hypoperfusion and guide fluid administration. Blood pressure (noninvasive) can be obtained continuously using the finger cuff technology and the cardiac output is effortlessly achieved using the pulse contour method. Therefore, completely non-invasive hemodynamic monitoring system provides continuous blood pressure as well as cardiac output measurement for medical use in all the patients that would otherwise not be monitored in that particular patient. The main assessment of the hemodynamic condition is performed by assessing heart rate (HR) and the mean blood pressure (BP) as a substitute of tissue perfusion. When the abovementioned parameters change speedily, a single measurement of the condition conveys inadequate information, thereby making incessant measurement desirable and for this reason why hemodynamic monitoring system is preferred. For nonstop measurement of blood pressure, cannulation of the artery affected is the basic approach. Nonetheless, continuous and noninvasive monitoring of BP has many advantages, mainly if the intra-arterial measurement of blood pressure is not warranted whilst intermittent measurement does not have required time resolution. The finger cuff technology is capable of offering such noninvasive and continuous monitoring of BP as well as other hemodynamics parameters. Owing to these factors, the global non-invasive hemodynamic monitoring system market is expected to experience a steady growth during the forecast period.
Hemodynamic monitoring systems are primarily used for medical inspection of cardiovascular health, quality and longevity of life of patients undergoing as well as recovering from cardiac surgery. The aforementioned parameters are typically measured by using photometric, electrical, pressure transducing equipment and invasive as well as noninvasive devices. Hemodynamic monitoring systems use various intravascular catheters as well. Some of the factors boosting the demand for non-invasive hemodynamic monitoring systems are rising incidences of respiratory disorders, growing occurrence of lifestyle diseases, increasing demand for screening of CCHD or critical congenital heart disease, private as well as government initiatives to decrease healthcare costs and increasing geriatric population across the world.
Get PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/405
Non-invasive hemodynamic monitoring system market taxonomy
On the basis of application, the market is classified into:
Anesthesiology
Emergency care
Cardiology
On the basis of end-user, the market is classified into:
Hospitals
Cath Labs
Home and Ambulatory Care
Increasing prevalence of heart diseases will drive the overall non-invasive hemodynamic monitoring system market
According to Center for Disease Control and Prevention, in 2015, around 28.4 million people were diagnosed with heart diseases in the U.S. alone, i.e., around 11.7% of the population. This number is expected to rise in the near future, owing to changes in lifestyle and food habits. Since heart diseases require constant monitoring of hemodynamic, the overall non-invasive hemodynamic monitoring systems market is likely to gain momentum during the forecast period.
Technological advancements and initiatives are being adopted by industry players to boost the U.S. market. Also, rising usage of heart patient monitoring systems in Canada, high diabetes prevalence are likely to boost the market for non-invasive hemodynamic monitoring system in North America. Asia-Pacific is expected to account for the second-largest share of the market. In the coming years, non-invasive hemodynamic monitoring system market is expected to witness the highest growth in the Asia-Pacific region, with China, Japan, and India positioned as growth engines. In the Asia Pacific, especially in countries such as India and China, the demand for non-invasive hemodynamic monitoring system is expected to gain significant traction. According to American Diabetic Association, around 60% of the world’s diabetic population lives in Asia. The prevalence of diabetes in India and China is 8.6% and 9.6% respectively. India is known as the diabetes capital of the world with more than 60 million diabetics in the country as of 2014. Factors such as aging population in and high prevalence of diabetes in, increasing prevalence of cardiac diseases, and increase in healthcare spending by the population in emerging economies such as India, China, and Brazil, are driving the growth of the market in these regions.
Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/405
The key players of the non-invasive hemodynamic monitoring system market are Pulsion Medical Systems SE, Edwards Lifesciences Corporation, and LiDCO Group plc. These companies together contributed to about more than half of the market in 2016. The other players of the market are Deltex Medical Group Plc., Cheetah Medical Inc., ICU Medical, Inc., Hemo Sapiens, In., Schwarzer Cardiotek GmbH, Osypka Medical GmbH, and Tensys Medical, Inc.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Non-Invasive Hemodynamic Monitoring System Market–,2017–2025
Global geriatric care services market is expected to reach USD 1,012.02 billion by 2022, according to a new study by Grand View Research, Inc.
Constantly increasing geriatric population prone to chronic medical conditions is expected to drive market growth over the forecast period.
In 2012, according to data published by the Center of Disease Control (CDC) it has been estimated that nearly 95% nursing homes, 77% adult day care service centers, 78% home health agencies and 52% residential care communities were certified to participate in Medicaid.
Furthermore, nearly 99% home health agencies, 100% hospice, and 96.5% nursing homes were Medicare certified.Further key findings from the study suggest:The home care services market was valued at 255.36 billion in 2014 and is expected to grow at a healthy rate over the forecast period.
Services include medical and non-medical services.Institutional care services were the leading segment of the market in 2014.
Large presence and high usage rates of institutions offering geriatric care services such as nursing homes, assisted living facilities, hospital based geriatric care and independent senior living communities is a key factor attributing to its market position.
Microalbumin Test Market Research Report: By Product (Analyzer, Reagent Kit, Control Kit, Micro-Cuvettes, Test Strips), Indication (Kidney Disease, Diabetes, High Blood Pressure), End User (Hospitals, Diagnostics Laboratories) – Global Forecast till 2027Market HighlightsMicroalbumin test is one of the vital urine tests for the diagnosis of diabetes, kidney diseases, and diabetic retinopathy.
Analyzer, reagent kit, control kit, micro-cuvettes, and test strips are various devices used in the microalbumin test.
Hematuria (blood in the urine), certain medications, fever, vigorous exercise, urinary tract infection are some of the factors leading to the elevated levels of microalbumin in the urine.The market is driven by the increasing prevalence of diabetes, renal dysfunction, and other kidney problems.
In addition, increasing research and development activities, and technological advancements in medical device sector are fuelling the global microalbumin test market growth.
The growth of the market is restricted by the accuracy and reliability of tests and the high cost of diagnostic devices.The global microalbumin test market is expected to grow at a CAGR of 5.1% during the forecast period.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5307Major Players in Microalbumin test MarketSome of the key players in the global market are Beckman Coulter (U.S.), Siemens (Germany), Nova Biomedical (U.S.), Roche (Switzerland), Abbott (U.S.), URIT Medical (China), ARKRAY (Japan), OPTI Medical (U.S.), ACON Laboratories (US), Sysmex (Japan), 77 Elektronika (Hungary), and Randox Laboratories (U.K).Taste the market data and market information presented through more than 55 market data tables and figures spread over 101 pages of the project report.
Avail the in-depth table of content (TOC) & market synopsis on “Microalbumin test market research report–Global forecast till 2023.”Regional AnalysisThe market for the microalbumin test is found to be increasing in the Americas.
Aug 09, 2019 (AB Digital via COMTEX) -- Market Trends
The global Cardiac Rehabilitation Devices Market is projected to reach over USD 2,839.9 million by 2023 at 6.2% CAGR during the review period of 2018 to 2023.
Cardiac rehabilitation is a medically managed program designed to improve cardiovascular health.
The rising prevalence of cardiac diseases, adoption of an unhealthy lifestyle and increasing geriatric population are driving the growth of the global cardiac rehabilitation devices market.
However, the factor such as the high cost of cardiac rehabilitation devices and stringent government regulations hinders market growth.
Cardiac Rehabilitation Devices Market Leading Companies:
Oxygen Therapy Systems Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Global Oxygen Therapy Systems market industry with an attention on the Global market.
The report gives key insights available status of the Global Oxygen Therapy Systems producers and is an important wellspring of direction and course for organizations and people keen on the business.
By and large, the report gives an inside and out understanding of 2020-2025 worldwide Oxygen Therapy Systems Market covering extremely significant parameters.Brief Summary of Oxygen Therapy Systems:Oxygen therapy system provides oxygen at a concentration pressure greater than that is found in the environmental atmosphere.
Many biochemical reactions in the body depend on the use of oxygen.
Supply of oxygen to the tissues depends on many factors like ventilation, diffusion across alveolar-capillary membrane, haemoglobin, cardiac output, and tissue perfusion.
Oxygen therapy system is required for respiratory failure in many conditions like severe asthma, chronic bronchitis, pneumonia, and myocardial infarction, etc.
Respiratory Devices and Equipment (Therapeutic) Market:WiseGuyReports.com adds “Global Respiratory Devices and Equipment (Therapeutic) Market Research Report 2020-30” reports to its database.Executive SummaryThe global respiratory devices and equipment (therapeutic) market is expected to grow from $13.4 billion in 2019 to about $33.5 billion in 2020 as these are important equipment used in treatment of respiratory diseases such as Covid-19.
Companies across the globe are focusing on increasing the availability of ventilators, nebulizers and other respiratory support devices for the patients.The respiratory devices and equipment therapeutic market consists of sales of respiratory devices and equipment used to treat patients with acute or chronic respiratory disorders such as chronic obstructive pulmonary disease (COPD), chronic bronchitis, asthma, sleep disorders, etc.
The market includes the sales of respiratory monitoring devices establishments primarily engaged in the manufacturing of nebulizers, humidifiers, oxygen concentrators, positive airway pressure devices, ventilators, capnographs, and gas analyzers.Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/5226496-respiratory-devices-and-equipment-therapeutic-global-market-reportNorth America was the largest region in the respiratory devices and equipment (therapeutic) market in 2019.The therapeutic respiratory devices and equipment market covered in this report is segmented by product into nebulizers, humidifiers, oxygen concentrators, positive airway pressure devices, ventilators, capnographs, gas analyzers and by end-user into homecare settings, hospitals.Rising prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Disorder (COPD) and sleep apnea contributed to the growth of the therapeutic respiratory devices and equipment market.
According to World Health Organization, one million people die due to chronic obstructive pulmonary diseases caused by smoking among the 4.9 million people who die due to tobacco consumption and 65 million people suffer with moderate to severe COPD.
As per its estimates, COPD is predicted to be the third leading cause of death worldwide and potentially fatal respiratory diseases.
According to Centers for Disease Control and Prevention (CDC), there were approximately 12.7 million adults aged over 18 reported to have COPD in the U.S.
Connective Tissue Disease Market Research Report information: Diagnosis (X-ray Examination, Antinuclear Antibody Test, Treatment (Non-Steroidal Anti-Inflammatory, Cortisone/Steroids, Antimalarial, Cytotoxic Drugs), End User - Global forecast till 2027Market HighlightsConnective tissue disease is a group of medical diseases.
Various connective tissue disorders feature abnormal immune system activity along with inflammation in tissues.
Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels.According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population.
It is also reported that among Asian population, the condition is more prevalent in China, and Japan.
In the European region, the disorder is more prevalent in Italy, Hungary, Norway and Poland.Rising prevalence of connective tissue disease, high unmet needs of current treatment, and increase in research and development expenditure will promote the growth of connective tissue disease market.Lack of infrastructure in the middle and low income countries may hamper the growth of the market.It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/4977Regional AnalysisThe Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure.
As per the facts suggested by the Centers for Disease Control and Prevention (CDC), it is found that out of total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.Europe holds the second position in the connective tissue disease market.
ICD sends small electrical impulses to the lower chambers of the heart to help them beat in more synchronized patterns and reduce symptoms.
Thus, ICD provides a treatment option to correct heart rates that are too fast and can lead to sudden cardiac arrest.
The global implantable cardioverter defibrillator (ICD) market is growing at a rapid pace.
Conversely, the high cost of ICDs involved in therapeutic surgeries acts as a major growth impeder for the market.
Also, stringent government regulations for product approvals restrict market growth, delaying launches of advanced products.
Besides, side-effects related to medications are projected to restrain market growth during the forecast period.Implantable Cardioverter Defibrillator (ICD) Market – SegmentsThe report is segmented into four dynamics;By Product: Regular ICD, Cardiac Resynchronization Therapy Defibrillators (CRT-D), Subcutaneous-ICD (S-ICD), and others.By Indication: Myocardial Ischemia, Acute Myocardial Infarction, Electrolyte Imbalance, Drug Toxicity, and others.By End User: Ambulatory Surgical Centers, Hospitals & Clinics, and others.By Regions: Americas, Europe, Asia Pacific, and Rest-of-the-world.Global ICD Market – Regional AnalysisNorth America dominates the global implantable cardioverter defibrillator (ICD) market.
Global Costochondritis Market Size Research Report, by Diagnosis (Cardiac MRI Tests, CT scan), Treatment (Medications and Surgery), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Research Centers) – Global Forecast Till 2023Costochondritis is the most common rib inflammatory disease.
Costochondritis can be caused due to repeated exercise and result in chest pain.The costochondritis market is expected to witness tremendous growth owing to the rising prevalence of various cardiovascular diseases, car accidents, and certain respiratory conditions, such as syphilis.
It can also be caused due to tuberculosis or virus infections that can cause some inflammation, and rising hypertension cases as well.
It is estimated that the Global Costochondritis Market Size is expected to register an increasing CAGR during the forecast period from 2018 to 2023Other key factors such as the change to a sedentary lifestyle and inflammatory heart diseases are contributing towards the growth of the market.
Such an incidence rate of hypertension promotes market growth.However, factors such as high cost of surgical procedures, expensive treatments, lack of awareness about the treatment, and the side effects associated with medication are expected to hinder the growth of the costochondritis market during the forecast period.Key Players Some of the key players in the global costochondritis market are KemPharm, GlaxoSmithKline plc, Biovail Corporation, Aurobindo Pharma, Pfizer Inc., Recro Pharma Inc., LUPIN, Bausch Health Companies Inc., Avenue Therapeutics, and others.SegmentationThe global costochondritis market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.Browse More Information @ https://www.marketresearchfuture.com/reports/costochondritis-market-6500Regional AnalysisThe Americas is the largest in the market owing to the increasing prevalence of rheumatic heart disorders, increasing tuberculosis cases, and growing healthcare expenditure.
Global geriatric care services market is expected to reach USD 1,012.02 billion by 2022, according to a new study by Grand View Research, Inc.
Constantly increasing geriatric population prone to chronic medical conditions is expected to drive market growth over the forecast period.
In 2012, according to data published by the Center of Disease Control (CDC) it has been estimated that nearly 95% nursing homes, 77% adult day care service centers, 78% home health agencies and 52% residential care communities were certified to participate in Medicaid.
Furthermore, nearly 99% home health agencies, 100% hospice, and 96.5% nursing homes were Medicare certified.Further key findings from the study suggest:The home care services market was valued at 255.36 billion in 2014 and is expected to grow at a healthy rate over the forecast period.
Services include medical and non-medical services.Institutional care services were the leading segment of the market in 2014.
Large presence and high usage rates of institutions offering geriatric care services such as nursing homes, assisted living facilities, hospital based geriatric care and independent senior living communities is a key factor attributing to its market position.
Microalbumin Test Market Research Report: By Product (Analyzer, Reagent Kit, Control Kit, Micro-Cuvettes, Test Strips), Indication (Kidney Disease, Diabetes, High Blood Pressure), End User (Hospitals, Diagnostics Laboratories) – Global Forecast till 2027Market HighlightsMicroalbumin test is one of the vital urine tests for the diagnosis of diabetes, kidney diseases, and diabetic retinopathy.
Analyzer, reagent kit, control kit, micro-cuvettes, and test strips are various devices used in the microalbumin test.
Hematuria (blood in the urine), certain medications, fever, vigorous exercise, urinary tract infection are some of the factors leading to the elevated levels of microalbumin in the urine.The market is driven by the increasing prevalence of diabetes, renal dysfunction, and other kidney problems.
In addition, increasing research and development activities, and technological advancements in medical device sector are fuelling the global microalbumin test market growth.
The growth of the market is restricted by the accuracy and reliability of tests and the high cost of diagnostic devices.The global microalbumin test market is expected to grow at a CAGR of 5.1% during the forecast period.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5307Major Players in Microalbumin test MarketSome of the key players in the global market are Beckman Coulter (U.S.), Siemens (Germany), Nova Biomedical (U.S.), Roche (Switzerland), Abbott (U.S.), URIT Medical (China), ARKRAY (Japan), OPTI Medical (U.S.), ACON Laboratories (US), Sysmex (Japan), 77 Elektronika (Hungary), and Randox Laboratories (U.K).Taste the market data and market information presented through more than 55 market data tables and figures spread over 101 pages of the project report.
Avail the in-depth table of content (TOC) & market synopsis on “Microalbumin test market research report–Global forecast till 2023.”Regional AnalysisThe market for the microalbumin test is found to be increasing in the Americas.
Connective Tissue Disease Market Research Report information: Diagnosis (X-ray Examination, Antinuclear Antibody Test, Treatment (Non-Steroidal Anti-Inflammatory, Cortisone/Steroids, Antimalarial, Cytotoxic Drugs), End User - Global forecast till 2027Market HighlightsConnective tissue disease is a group of medical diseases.
Various connective tissue disorders feature abnormal immune system activity along with inflammation in tissues.
Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels.According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population.
It is also reported that among Asian population, the condition is more prevalent in China, and Japan.
In the European region, the disorder is more prevalent in Italy, Hungary, Norway and Poland.Rising prevalence of connective tissue disease, high unmet needs of current treatment, and increase in research and development expenditure will promote the growth of connective tissue disease market.Lack of infrastructure in the middle and low income countries may hamper the growth of the market.It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/4977Regional AnalysisThe Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure.
As per the facts suggested by the Centers for Disease Control and Prevention (CDC), it is found that out of total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.Europe holds the second position in the connective tissue disease market.
ICD sends small electrical impulses to the lower chambers of the heart to help them beat in more synchronized patterns and reduce symptoms.
Thus, ICD provides a treatment option to correct heart rates that are too fast and can lead to sudden cardiac arrest.
The global implantable cardioverter defibrillator (ICD) market is growing at a rapid pace.
Conversely, the high cost of ICDs involved in therapeutic surgeries acts as a major growth impeder for the market.
Also, stringent government regulations for product approvals restrict market growth, delaying launches of advanced products.
Besides, side-effects related to medications are projected to restrain market growth during the forecast period.Implantable Cardioverter Defibrillator (ICD) Market – SegmentsThe report is segmented into four dynamics;By Product: Regular ICD, Cardiac Resynchronization Therapy Defibrillators (CRT-D), Subcutaneous-ICD (S-ICD), and others.By Indication: Myocardial Ischemia, Acute Myocardial Infarction, Electrolyte Imbalance, Drug Toxicity, and others.By End User: Ambulatory Surgical Centers, Hospitals & Clinics, and others.By Regions: Americas, Europe, Asia Pacific, and Rest-of-the-world.Global ICD Market – Regional AnalysisNorth America dominates the global implantable cardioverter defibrillator (ICD) market.
Aug 09, 2019 (AB Digital via COMTEX) -- Market Trends
The global Cardiac Rehabilitation Devices Market is projected to reach over USD 2,839.9 million by 2023 at 6.2% CAGR during the review period of 2018 to 2023.
Cardiac rehabilitation is a medically managed program designed to improve cardiovascular health.
The rising prevalence of cardiac diseases, adoption of an unhealthy lifestyle and increasing geriatric population are driving the growth of the global cardiac rehabilitation devices market.
However, the factor such as the high cost of cardiac rehabilitation devices and stringent government regulations hinders market growth.
Cardiac Rehabilitation Devices Market Leading Companies:
Global Costochondritis Market Size Research Report, by Diagnosis (Cardiac MRI Tests, CT scan), Treatment (Medications and Surgery), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Research Centers) – Global Forecast Till 2023Costochondritis is the most common rib inflammatory disease.
Costochondritis can be caused due to repeated exercise and result in chest pain.The costochondritis market is expected to witness tremendous growth owing to the rising prevalence of various cardiovascular diseases, car accidents, and certain respiratory conditions, such as syphilis.
It can also be caused due to tuberculosis or virus infections that can cause some inflammation, and rising hypertension cases as well.
It is estimated that the Global Costochondritis Market Size is expected to register an increasing CAGR during the forecast period from 2018 to 2023Other key factors such as the change to a sedentary lifestyle and inflammatory heart diseases are contributing towards the growth of the market.
Such an incidence rate of hypertension promotes market growth.However, factors such as high cost of surgical procedures, expensive treatments, lack of awareness about the treatment, and the side effects associated with medication are expected to hinder the growth of the costochondritis market during the forecast period.Key Players Some of the key players in the global costochondritis market are KemPharm, GlaxoSmithKline plc, Biovail Corporation, Aurobindo Pharma, Pfizer Inc., Recro Pharma Inc., LUPIN, Bausch Health Companies Inc., Avenue Therapeutics, and others.SegmentationThe global costochondritis market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.Browse More Information @ https://www.marketresearchfuture.com/reports/costochondritis-market-6500Regional AnalysisThe Americas is the largest in the market owing to the increasing prevalence of rheumatic heart disorders, increasing tuberculosis cases, and growing healthcare expenditure.
Oxygen Therapy Systems Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Global Oxygen Therapy Systems market industry with an attention on the Global market.
The report gives key insights available status of the Global Oxygen Therapy Systems producers and is an important wellspring of direction and course for organizations and people keen on the business.
By and large, the report gives an inside and out understanding of 2020-2025 worldwide Oxygen Therapy Systems Market covering extremely significant parameters.Brief Summary of Oxygen Therapy Systems:Oxygen therapy system provides oxygen at a concentration pressure greater than that is found in the environmental atmosphere.
Many biochemical reactions in the body depend on the use of oxygen.
Supply of oxygen to the tissues depends on many factors like ventilation, diffusion across alveolar-capillary membrane, haemoglobin, cardiac output, and tissue perfusion.
Oxygen therapy system is required for respiratory failure in many conditions like severe asthma, chronic bronchitis, pneumonia, and myocardial infarction, etc.
Respiratory Devices and Equipment (Therapeutic) Market:WiseGuyReports.com adds “Global Respiratory Devices and Equipment (Therapeutic) Market Research Report 2020-30” reports to its database.Executive SummaryThe global respiratory devices and equipment (therapeutic) market is expected to grow from $13.4 billion in 2019 to about $33.5 billion in 2020 as these are important equipment used in treatment of respiratory diseases such as Covid-19.
Companies across the globe are focusing on increasing the availability of ventilators, nebulizers and other respiratory support devices for the patients.The respiratory devices and equipment therapeutic market consists of sales of respiratory devices and equipment used to treat patients with acute or chronic respiratory disorders such as chronic obstructive pulmonary disease (COPD), chronic bronchitis, asthma, sleep disorders, etc.
The market includes the sales of respiratory monitoring devices establishments primarily engaged in the manufacturing of nebulizers, humidifiers, oxygen concentrators, positive airway pressure devices, ventilators, capnographs, and gas analyzers.Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/5226496-respiratory-devices-and-equipment-therapeutic-global-market-reportNorth America was the largest region in the respiratory devices and equipment (therapeutic) market in 2019.The therapeutic respiratory devices and equipment market covered in this report is segmented by product into nebulizers, humidifiers, oxygen concentrators, positive airway pressure devices, ventilators, capnographs, gas analyzers and by end-user into homecare settings, hospitals.Rising prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Disorder (COPD) and sleep apnea contributed to the growth of the therapeutic respiratory devices and equipment market.
According to World Health Organization, one million people die due to chronic obstructive pulmonary diseases caused by smoking among the 4.9 million people who die due to tobacco consumption and 65 million people suffer with moderate to severe COPD.
As per its estimates, COPD is predicted to be the third leading cause of death worldwide and potentially fatal respiratory diseases.
According to Centers for Disease Control and Prevention (CDC), there were approximately 12.7 million adults aged over 18 reported to have COPD in the U.S.